A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes

Inclusion Criteria: * Male or female, age above or equal to 50 years at the time of signing informed consent * Body mass index equal to or less than 39.9 kg/m\^2 * Diagnosed with type 2 diabetes 180 daysor more prior to the day of the first screening visit * HbA1c 6.0% - 9.0% (42-75 mmol/mol) (both inclusive) * Established cardiovascular disease Exclusion Criteria: * Hospitalisation for unstable angina pectoris or transient ischaemic attack within 90 days prior to the day of the first screening visit * Planned coronary, carotid or peripheral artery revascularisation. * Presently classified as being in New York Heart Association (NYHA) equal to or above Class III * Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or systemic anti-inflammatory drugs within 90 days prior to the first screening visit. Stable treatment with acetylsalicylic acid for prevention of cardiovascular events and occasional use of propionic acid derivatives drugs (e.g. ibuprofen) is allowed